Inogen, Inc. announced that Jason Richardson will assume the role of Chief Financial Officer effective April 6, 2026. Richardson joins the company after a distinguished career in corporate finance, most recently serving as Vice President of Finance at Baxter International and as Director of Capital Markets at Hillrom. His experience is expected to strengthen financial oversight as Inogen expands its product portfolio and pursues new growth opportunities.
The appointment follows a broader executive‑team restructuring that also saw Dominic Hulton named Chief Marketing Officer and Corey Moritz promoted to Vice President of U.S. Business‑to‑Business Sales. The changes are part of Inogen’s strategy to accelerate profitability and broaden its market reach. Inogen’s full‑year 2025 results showed a net loss of $22.7 million on revenue of $348.7 million, but the company achieved a positive adjusted EBITDA of $2.7 million, a turnaround from a $9.5 million loss in 2024. The new CFO will oversee the financial execution of this turnaround and the launch of new products such as the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks.
Management highlighted the need for stronger financial stewardship as the company navigates a shifting reimbursement landscape and intensifying competition from Philips Respironics, ResMed, and CAIRE. CEO Kevin Smith said, "Jason’s deep expertise in finance and operations across the medical device and healthcare industries will be instrumental as we focus on delivering superior respiratory solutions to patients around the world and driving sustainable growth." Smith also noted that outgoing CFO Michael Bourque will remain in an advisory role until June 30, 2026, ensuring continuity during the transition.
Inogen’s 2026 revenue outlook has been reaffirmed at $366 million to $373 million, representing roughly 6 % growth from 2025. The company’s guidance reflects confidence in its expanded product line and its growing business‑to‑business channel, particularly in international markets such as China through a partnership with Yuwell Medical. The CFO’s role will be critical in managing the company’s capital structure, cost discipline, and strategic investments needed to sustain this growth trajectory.
The appointment signals Inogen’s commitment to disciplined financial management amid a competitive market. With a history of net losses and a recent shift toward positive adjusted EBITDA, the company’s leadership is positioning itself to capitalize on new product launches and market expansion while maintaining a focus on profitability and operational efficiency.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.